February 28, 2017
Sanofi has submitted a new drug application for the human monoclonal antibody dupilumab for the treatment of atopic dermatitis, the company announced on February 27. Dupilumab selectively inhibits the signaling of IL-4 and IL-13 proteins, which play a central role...read more